SCHEMBL29214926

SCHEMBL29214926

CCOc1ccc(-c2nc(C(=O)N/N=C/c3cc(OC)cc(OC)c3)cnc2N)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.48
▸ ALDH1A1 P00352 6/20 0.48
▸ KDM4E B2RXH2 5/20 0.48
▸ HPGD P15428 4/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ TP53 P04637 1/20 0.45
▸ LMNA P02545 2/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ MGAM O43451 1/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ POLB P06746 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ TDP1 Q9NUW8 2/20 0.42
▸ THRB P10828 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29214940 1.00 MAPT (0.48) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL29214880 0.90 KMT2A (0.48) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL24994782 0.90 KMT2A (0.48) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL24994777 0.90 KMT2A (0.48) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL30925922 0.90 MEN1 (0.48) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL24994779 0.89 KMT2A (0.47) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL29214987 0.89 KMT2A (0.47) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL29214993 0.89 KMT2A (0.47) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL30925906 0.87 MEN1 (0.46) MAPTALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL29215094 0.87 MEN1 (0.46) MAPTALDH1A1KDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 — — US claimed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN claimed
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS UNIVERSIDADE FEDERAL DO RIO DE JANEIRO – UFRJ (BR) 2024-10-10 — — US disclosed
CN-118076348-A N-acylhydrazone compounds capable of inhibiting NAV 1.7 and/or NAV 1.8, methods of making, compositions, uses, methods of treatment and kits using the same 欧罗法玛实验室股份公司 2024-05-24 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240335442-A1 N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS SCN1A, SCN7A, SCN8A MAPT 3908/4885ALDH1A1 320/4885KDM4E 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback